Loading…
Employees: 3,069
Size Morepen Laboratories (MOREPENLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $529M, the 818th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹92.25 on 6 Nov 2026.
Performance Over six months the shares gained 109.5%, against -16.1% for the median peer and 0.0% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 30.2% over the last twelve months (peer median +9.4%); the operating margin is 10.6% (peer median 6.8%).
Valuation It trades at 2.2× enterprise value to sales against a peer median of 4.1× (5th cheapest of 18).
Capital Return on invested capital runs 3.5 points below its cost of capital (16.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹22.9B | ₹18.0B | ₹18.1B | ₹16.8B | ₹14.1B |
| Revenue growth | — | 0% | +7% | +19% | — |
| Gross profit | ₹6.34B | ₹3.18B | ₹3.17B | ₹3.26B | ₹2.19B |
| EBITDA | ₹2.76B | ₹1.22B | ₹1.70B | ₹1.50B | ₹764M |
| Net income | ₹1.89B | ₹949M | ₹1.18B | ₹962M | ₹387M |
| Free cash flow | n/a | -₹693M | -₹1.00B | -₹117M | -₹1.39B |
| Capital expenditure | n/a | ₹2.04B | ₹2.38B | ₹813M | ₹460M |
| Total debt | ₹3.23B | ₹2.08B | ₹1.05B | ₹290M | ₹252M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MOREPENLAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -37.2% | -10.0% | lowest of 21 |
| 6-month return | +109.5% | -16.1% | 2nd highest of 21 |
| Distance from 52-week high | -38.8% | -32.1% | 9th lowest of 21 |
| Revenue growth (TTM) | +30.2% | +9.4% | 3rd highest of 20 |
| Operating margin | 10.6% | 6.8% | 8th highest of 18 |
| EV / Sales | 2.2× | 4.1× | 5th cheapest of 18 |
| ROIC minus cost of capital | -3.5 pp | -2.6 pp | 9th lowest of 19 |
| EV / EBITDA | 18.3× | 22.1× | 2nd cheapest of 4 |
| Net debt / EBITDA | 0.2× | 1.1× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |